Best Life Sciences Companies in Dallas, United States
The 104 best Life Sciences companies in Dallas, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Verily.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Dallas
| # | Company | Disclosed funding | Last round | Employees | Founder | Web popularity | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Verily 🦄 A data platform and technology company purpose-built to power AI-enabled precision health 84News top 13%Funding top 14%Talent top 22%Growth top 25% All 12 signals ▾Newstop 13% Fundingtop 14% Talenttop 22% Growthtop 25% Moattop 26% Techtop 30% Markettop 31% Producttop 32% Customerstop 34% Partnerstop 41% Innovationtop 42% Globaltop 48% News: 7 BI events in 12 mo (of 67 tracked, 9 types) · +600% YoY Funding: Raised $2.5B across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 84/100 | $2.5B | 3 mo ago | 1,564 | Andrew Conrad Co-Founder | Top 5M | Series D | — | — |
| 2 | Peloton Therapeutics Developer of small molecule therapeutics to treat kidney cancer | $243M | 88 mo ago | 62 | Steven McKnight Co-Founder | — | Acquired | 150 patents Develops small-molecule oncology drugs targeting HIF-2α, Hippo pathway, and novel scaffolds. | — |
| 3 | Taysha Gene Therapies Developer of gene-based therapies for treating CNS disorders | $125M | 34 mo ago | 183 183 → 134 (-27%) | R.A. Session Founder & CEO | Top 10M | Public | — | — |
| 4 | MicroTransponder Developer of neuromodulation therapy for neurological conditions | $115M | 15 mo ago | 33 | Jordan Curnes Co-Founder & President | Top 50M | Series F | 87 patents Vagus nerve stimulation integrated with motor and therapeutic rehabilitation devices | — |
| 5 | Inotek Pharma Developer of therapies to treat glaucoma and other diseases of the eye | $112M | 118 mo ago | 7 | — | — | Public | — | — |
| 6 | ReCode Therapeutics Developer of precision medicines for pulmonary diseases | $82M | 74 mo ago | — | Michael Torres Co-Founder | — | Series A | — | — |
| 7 | Vaxxinity Developer of vaccines for neurological disorders and infectious diseases | $27M | 62 mo ago | 92 | — | Top 50M | Public | 34 patents Peptide immunotherapy targeting tau, amyloid‑beta and synuclein in neurodegenerative diseases | — |
| 8 | Secretome Therapeutics Developer of cell-based therapies for multiple diseases | $22M | 0 mo ago | 8 | Sudhish Sharma Co-Founder | Top 10M | Series A | — | — |
| 9 | Ideal Implant Medical device and biologics company innovating tissue and cell-based technologies | $17M | 67 mo ago | 15 | Robert S. Hamas Founder & CEO | — | Acquired | 25 patents Patents concentrated in health & consumer products | — |
| 10 | precision biologics Precision Biologics develops therapeutic and diagnostic products for the early detection and treatment of… | $15M | 146 mo ago | 7 | — | Top 50M | Acquired | 15 patents Therapeutic antibodies targeting tumor antigens and immunosuppressive cells in cancer. | — |
| 11 | Cersci Therapeutics Global technology company providing cutting-edge solutions for the ready-mix concrete industry | $12M | 75 mo ago | 17 | — | — | Acquired | — | — |
| 12 | ImmuneSensor Developer of small-molecule drugs to treat cancer | $10M | 42 mo ago | 11 11 → 9 (-18%) | — | — | Series A | — | — |
| 13 | Dose Therapeutics Developer of protein degradation therapeutics for children with neuroblastoma | $10M | 49 mo ago | — | Deepak Nijhawan Co-Founder | — | Series A | — | — |
| 14 | Six Month Smiles Fast, affordable teeth straightening solutions with clear braces and aligners | $8M | 136 mo ago | 45 | Perry S. Lowe CEO | Top 10M | Acquired | 8 patents Orthodontic bracket systems and kits for dental alignment and treatment. | — |
| 15 | Lantern Pharma Developing drug and companion diagnostics for multi-drug resistant cancers | $7M | 53 mo ago | 23 23 → 30 (+30%) | Panna Sharma Chief Executive Officer | Top 50M | Public | — | 2 job openings · 1 launch |
| 16 | Dialectic Therapeutics Developer of therapeutic solutions for treating cancer | $7M | 64 mo ago | 6 | David Genecov Co-Founder & CEO & Managing Director & President | — | Series A | — | — |
| 17 | Belluscura Provider of medical devices for laparoscopic procedures | $6M | 16 mo ago | 21 | — | Top 10M | Public | 31 patents Respiratory support and oxygen therapy devices, including concentrators, ventilators, and ECMO systems. | — |
| 18 | GenrAb Developer of neuroprotective monoclonal antibodies for treating neurological disorders | $6M | 14 mo ago | — | Larry Tiffany CEO | — | Seed | — | — |
| 19 | Bone Solutions Provider of ornithological bone void filler bio-materials | $4M | 123 mo ago | 5 | — | — | Series A | 294 patents Orthopedic fixation implants and bone cement delivery systems for spine, pelvis, and long bones | 1 launch · 1 partnership |
| 20 | Socrates Health Non-invasive blood glucose monitoring sensor | $4M | 120 mo ago | 3 | — | — | Seed | — | — |
| 21 | Integrated Surgical Systems Orthopedic robotic system for use in hip and knee replacements | $4M | 216 mo ago | — | Christopher Marlett CEO | — | Deadpooled | — | — |
| 22 | Surgical Automations Developer of surgical robots for surgical procedures 10AI top 45%Funding bottom 47%Global bottom 36%Market bottom 17% All 4 signals ▾AItop 45% Fundingbottom 47% Globalbottom 36% Marketbottom 17% AI: Product described with: ai-based Funding: Raised $3.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 10/100 | $3M | 7 mo ago | 3 | — | — | Seed | — | — |
| 23 | PerioSciences Topically applied, antioxidant-based oral care products | $3M | 151 mo ago | 12 | Russell Moon Founder & CEO | Top 5M | Series A | — | 1 launch |
| 24 | Atrantil Natural digestive health solution relieving bloating and abdominal discomfort | $2M | 126 mo ago | — | — | Top 5M | Seed | — | — |
| 25 | SightStream Developer of of corneal edema and regenerative therapies | $2M | 8 mo ago | 3 | Jason Werner CEO | — | Seed | — | — |
| 26 | RxDestruct Medical waste management service provider | $2M | 102 mo ago | 6 | Mark Macdonell CEO | — | Seed | — | — |
| 27 | Bioprinting Laboratories Provider of pillar/perfusion plates for 3D cell and organoid culture | $1M | 15 mo ago | — | Moo-Yeal Lee Founder & CEO | — | Funding Raised | — | 1 launch · 3 awards |
| 28 | Spectral MD Develops of AI-based wound imaging system | $1M | 38 mo ago | 71 | Michael DiMaio Founder & CEO | — | Public | 81 patents Medical hyperspectral imaging systems and AI-driven tissue/wound analysis technologies. | — |
| 29 | Caddo Medical Developer of patent protected pre-filled nebulizer system | $1M | 101 mo ago | — | Dee Faram Founder & Chairman | — | Seed | — | — |
| 30 | Magnolia Diagnostics Diagnostic lab providing fast, accurate results for providers and patients | $938K | 101 mo ago | 21 | Kelly Bains Co-Founder | — | Seed | — | — |
| 31 | Qualia Oto Provider of software facilitating automation and optimization of transportation management | $816K | 14 mo ago | 5 | — | — | Funding Raised | — | 1 award |
| 32 | BioLum Sciences Innovative chemiluminescence solutions for drug discovery and early disease detection | $729K | 53 mo ago | 4 | — | — | Series A | — | — |
| 33 | Verde Science Manufacturer of cannabis based medicinal formulations | $679K | 141 mo ago | 2 | Harp Sangha Founder & CEO | — | Public | — | — |
| 34 | Odin Biotech Partners Domain marketplace offering secure transactions and buyer protection | $600K | 141 mo ago | — | Karl Csaky Founder and CMO | — | Series A | — | — |
| 35 | Avsana Labs Developer of point-of-care diagnostics for respiratory syncytial virus | $596K | 47 mo ago | — | Zhenpeng Qin Co-Founder | — | Funding Raised | — | — |
| 36 | Reproductive Solutions Developer of advanced sperm collection and processing technologies. | $300K | 71 mo ago | 5 | Diana Peninger President & CEO | — | Seed | 3 patents Precision livestock management software and insulated temperature-controlled transport containers | — |
| 37 | CancerGene Connect Provider of SaaS based genetic screening for cancer risk assesment | $300K | 116 mo ago | 7 | — | — | Acqui-Hired | — | — |
| 38 | Pinnacle Spine Group Innovating spinal fusion with advanced interbody systems and graft delivery | $250K | 175 mo ago | 5 | Zach Sowell CEO | — | Seed | 28 patents Spinal intervertebral implants and graft delivery/filling systems for vertebral fusion procedures. | — |
| 39 | Brainceuticals Developing and marketing nutritional products to help nourish the brain | $250K | 188 mo ago | — | Lawrence Schwartz Founder & CEO | — | Deadpooled | — | — |
| 40 | Hera Health Solutions Nanotechnology-enabled drug delivery platform transforming therapeutics into long-acting, effective therapies | $127K | 37 mo ago | 7 | Idicula Mathew Co-Founder & CEO | Top 50M | Seed | — | — |
| 41 | Aperture Bio Developer of in-vitro diagnostics for drug-resistant bacterial infections | $100K | 32 mo ago | — | Kevin Kuykendall CEO | — | Seed | — | — |
| 42 | Clinata Online Clinical Research Marketplace | $100K | 147 mo ago | — | Asker Ahmed Founder & CEO | — | Seed | — | — |
Top 12 Life Sciences companies in Dallas
#1
Verily 🦄Series D · Dallas, Texas · founded 2015 · 1564 employees$2.5Braised▾
A data platform and technology company purpose-built to power AI-enabled precision health. The company combine deep clinical, regulatory, and technological expertise to provide customers with patient-centric solutions that make healthcare more personal and precise. The solutions are designed to make healthcare data AI-ready and fit for purpose across care, research, and public health.
- Mar 2026Series D$300M
- Apr 2025Grant (prize money)$14.7M
- Sep 2022PE—
- Dec 2020PE$700M
#2
Series A · Dallas, Texas · founded 2018 · 8 employees$22.1Mraised▾
Developer of cell-based therapies for multiple diseases. It offers a lead product STM-21 to prevent the inflammatory toxicities of cancer treatment which include cisplatin-induced acute kidney injury. It also offers STM-01 a cellular therapy comprised of the neonatal MSCs for restoring cardiac function in a heart attack.
- Mar 2026Series B$250K
- Nov 2024Series B$20.4M
- Oct 2019Seed$1.5M
#3
Series F · Dallas, Texas · founded 2007 · 33 employees$115.4Mraised▾
Developer of neuromodulation therapy for neurological conditions. The company uses proprietary technology and product- microtransponder's product is the Vivistim Paired VNS System, for helping stroke survivors regain upper limb motor function after their stroke.
- Mar 2025Series F$65M
- Jun 2022Series E$73M
- Sep 2020Conventional Debt$5.8M
- Nov 2017Series C$11.6M
#4
Seed · Dallas, Texas · founded 2020 · 3 employees$3.4Mraised▾
Developer of surgical robots for surgical procedures. The company has developed an AI-based autonomous robotic navigation system for endoscopic diagnostic and interventional procedures.
- Oct 2025Seed$3.4M
#5
Seed · Dallas, Texas · founded 2022 · 3 employees$2Mraised▾
Developer of of corneal edema and regenerative therapies. It offers cytoprotectives and pro-regenerative technologies that reverse the death of cells in the ocular cell system to prevent and recover from ocular cell damage.
- Oct 2025Seed$1.8M
- Aug 2023Seed$250K
#6
Public · Dallas, Texas · founded 2015 · 21 employees$6.4Mraised▾
Provider of medical devices for laparoscopic procedures. It offers Passport a single-use, and disposable trocar (laparoscopic access device); Slyde- patient evacuation equipment ; Snap II - Level of Consciousness (LoC) device during general anesthesia, etc. The company aims to provide proprietary medical devices at affordable prices across a wide variety of treatment and diagnostic disciplines.
- Feb 2025Post IPO$5M
- Jun 2019Series A$954.5K
- Apr 2019Series A$649.3K
- May 2018Series A$603K
#7
Seed · Dallas, Texas · founded 2022$5.6Mraised▾
Developer of neuroprotective monoclonal antibodies for treating neurological disorders. It focuses on developing therapies that protect and treat patients with neurological diseases. The company's proprietary Antibody Gene Signature (AGS) technology identifies potentially therapeutic fully-human mAbs to treat neurological disorders. These antibodies leverage naturally created neuroprotective mechanisms found in individuals experiencing neurodegeneration. The company aims to prevent disease progression and provide neuroprotection.
- Apr 2025Seed$5.6M
#8
Public · Dallas, Texas · founded 2020 · 183 employees$125Mraised▾
Developer of gene-based therapies for treating CNS disorders. The company has developed an AAV9 capsid delivery system and Zolgensma is a gene-based therapy to treat CNS diseases. The pipeline includes TGTX-104, gene replacement therapy to treat Rett Syndrome (IND enabling), TGTX-106, short hairpin RNA, to treat Angelman, and more.
- Aug 2023Post IPO$150M
- Oct 2022Post IPO$50M
- Aug 2020Series B$95M
- May 2020Seed$30M
#9
Funding Raised · Dallas, Texas · founded 2020$1.4Mraised▾
Provider of pillar/perfusion plates for 3D cell and organoid culture. These plates facilitate static and dynamic culture, enabling organoid testing, imaging, and scaled-up production. The plates are designed for ease of use and compatibility with standard laboratory equipment. Applications include drug screening and disease modeling using human organoids, such as liver and brain organoids.
- Feb 2025Grant (prize money)$284.6K
- Aug 2023Grant (prize money)$284.6K
- Jul 2020Grant (prize money)$837.9K
#10
Funding Raised · Dallas, Texas · founded 2018 · 5 employees$815.7Kraised▾
Provider of software facilitating automation and optimization of transportation management. The software offers functionalities for planning, execution, and analysis of transportation activities. It enables businesses to streamline processes, reduce costs, and improve overall efficiency. The system provides tools for managing freight, optimizing routes, and tracking shipments.
- Apr 2025Grant (prize money)$304.7K
- Aug 2024Grant (prize money)$277.1K
- Apr 2022Grant (prize money)$233.9K
#11
Acquired · Dallas, Texas · founded 2010 · 62 employees$242.6Mraised▾
Peloton Therapeutics has developed small molecule therapies for life-threatening diseases. Its lead candidate, PT2385, is a HIF-2α inhibitor (completed phase 2 clinical trials) for the treatment of advanced or metastatic clear cell renal cell carcinoma (ccRCC). It is also developing PT2385 in combination with immuno-oncology drugs for the treatment of ccRCC, and for the treatment of solid tumors. The company is a subsidiary of Merck & Co.
- Feb 2019Series E$150M
- Mar 2017Series D$22.2M
- Sep 2016Series D$52.4M
- Oct 2014Series B—
#12
Public · Dallas, Texas · founded 1999 · 7 employees$111.9Mraised▾
Developer of therapies to treat glaucoma and other diseases of the eye. The product pipeline includes Trabodenoson entering clinical trial phase 3 for glaucoma and ocular hypertension, Trabodenoson and Latanoprost combination in clinical trial phase 2 for glaucoma and ocular hypertension.
- Aug 2016Post IPO$50M
- Sep 2013Venture Debt$7M
- Sep 2013Series E$14M
- Jul 2011Series D$23.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.